TheStreet cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a b- rating to a c rating in a report released on Thursday morning, TheStreetRatingsTable reports.
Other research analysts have also issued research reports about the company. BidaskClub lowered Amphastar Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, October 29th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, October 24th. Finally, ValuEngine lowered Amphastar Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, September 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $24.44.
Shares of Amphastar Pharmaceuticals stock traded down $0.71 during trading hours on Thursday, reaching $18.41. The stock had a trading volume of 600,700 shares, compared to its average volume of 195,968. Amphastar Pharmaceuticals has a 1 year low of $16.92 and a 1 year high of $25.43. The firm has a 50 day simple moving average of $19.87 and a two-hundred day simple moving average of $20.65. The company has a current ratio of 2.81, a quick ratio of 1.83 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $918.08 million, a price-to-earnings ratio of 87.67 and a beta of 1.17.
In related news, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $20.78, for a total transaction of $207,800.00. Following the completion of the transaction, the director now owns 49,309 shares in the company, valued at approximately $1,024,641.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Yakob Liawatidewi sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $20.73, for a total value of $103,650.00. Following the transaction, the senior vice president now owns 47,188 shares of the company’s stock, valued at approximately $978,207.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 354,479 shares of company stock valued at $7,415,153. Insiders own 30.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Amphastar Pharmaceuticals by 1.5% during the 2nd quarter. BlackRock Inc. now owns 5,927,141 shares of the company’s stock valued at $125,124,000 after acquiring an additional 87,107 shares in the last quarter. Vanguard Group Inc. raised its stake in Amphastar Pharmaceuticals by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 2,381,761 shares of the company’s stock valued at $50,279,000 after acquiring an additional 57,349 shares in the last quarter. Renaissance Technologies LLC raised its stake in Amphastar Pharmaceuticals by 33.2% during the 2nd quarter. Renaissance Technologies LLC now owns 588,000 shares of the company’s stock valued at $12,413,000 after acquiring an additional 146,400 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in Amphastar Pharmaceuticals during the 2nd quarter valued at $12,134,000. Finally, Northern Trust Corp raised its stake in Amphastar Pharmaceuticals by 1.3% during the 2nd quarter. Northern Trust Corp now owns 480,049 shares of the company’s stock valued at $10,133,000 after acquiring an additional 6,260 shares in the last quarter. Institutional investors and hedge funds own 47.21% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Recommended Story: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.